Literature DB >> 19411633

The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios.

Seema Singhal1, Eric Vickrey, Jairam Krishnamurthy, Veerpal Singh, Sharon Allen, Jayesh Mehta.   

Abstract

"Stringent" complete remission in myeloma has been defined by a normal serum free light chain ratio (SFLCR) in addition to the standard criteria for CR. 2648 serial samples from 122 IgG or IgA myeloma patients were studied to explore the relationship between SFLCR and serum immunofixation electrophoresis (SIFE). SFLCR was normal in 34% of cases with positive SIFE and abnormal in 66%. SFLCR was normal in 69% of cases with negative SIFE and abnormal in 31%. When evaluated with SIFE as the benchmark, the sensitivity of SFLCR was 66% and specificity was 69%. These findings were unchanged when abnormal SFLCR values were classified as concordant (< 0.26 for lambda disease and > 1.65 for kappa) or discordant (< 0.26 for kappa disease and > 1.65 for lambda). Additional studies are required to determine the temporal relationship between SFLCR normalization and paraprotein clearance. Until then, the role of SFLCR in defining response remains controversial.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19411633     DOI: 10.1182/blood-2009-02-205807

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Sensitivity of serum free light chain measurement of residual disease in multiple myeloma patients.

Authors:  Graham Peter Mead; Mark Trehane Drayson
Journal:  Blood       Date:  2009-08-20       Impact factor: 22.113

2.  Utility of serum free light chain ratio in response definition in patients with multiple myeloma.

Authors:  Nadine Abdallah; Prashant Kapoor; David L Murray; Francis K Buadi; David Dingli; Angela Dispenzieri; Morie A Gertz; Ronald S Go; Wilson I Gonsalves; Suzanne R Hayman; Taxiarchis V Kourelis; Martha Q Lacy; Nelson Leung; John A Lust; Eli Muchtar; Rahma Warsame; Robert A Kyle; S Vincent Rajkumar; Shaji K Kumar
Journal:  Blood Adv       Date:  2020-01-28

3.  Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients.

Authors:  Eric A Engels; Barbara Savoldo; Ruth M Pfeiffer; Rene Costello; Adriana Zingone; Helen E Heslop; Ola Landgren
Journal:  Transplantation       Date:  2013-02-15       Impact factor: 4.939

4.  Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies.

Authors:  Peter Mollee
Journal:  Clin Biochem Rev       Date:  2009-08

Review 5.  Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques.

Authors:  Noa Biran; Scott Ely; Ajai Chari
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 6.  Deep Response in Multiple Myeloma: A Critical Review.

Authors:  Mariateresa Fulciniti; Nikhil C Munshi; Joaquin Martinez-Lopez
Journal:  Biomed Res Int       Date:  2015-12-10       Impact factor: 3.411

7.  Multiple myeloma presented as acute renal failure.

Authors:  Ali Momeni; Ali Hajigholami; Hamid Nasri
Journal:  J Nephropharmacol       Date:  2013-07-01

8.  Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.

Authors:  Stefania Oliva; Manuela Gambella; Milena Gilestro; Vittorio Emanuele Muccio; Francesca Gay; Daniela Drandi; Simone Ferrero; Roberto Passera; Chiara Pautasso; Annalisa Bernardini; Mariella Genuardi; Francesca Patriarca; Elona Saraci; Maria Teresa Petrucci; Norbert Pescosta; Anna Marina Liberati; Tommaso Caravita; Concetta Conticello; Alberto Rocci; Pellegrino Musto; Mario Boccadoro; Antonio Palumbo; Paola Omedè
Journal:  Oncotarget       Date:  2017-01-24

9.  Evaluation of Correlation between Serum Free Light-Chain Assay and Bone Marrow Study in Multiple Myeloma Patients.

Authors:  Fatemeh Zamani; Mansoureh Shokripour; Maral Mokhtari
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2021-07-01

10.  Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma.

Authors:  R Silvennoinen; T Lundan; V Kairisto; T-T Pelliniemi; M Putkonen; P Anttila; V Huotari; P Mäntymaa; S Siitonen; L Uotila; T-L Penttilä; V Juvonen; T Selander; K Remes
Journal:  Blood Cancer J       Date:  2014-10-10       Impact factor: 11.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.